Your browser doesn't support javascript.
Immunomodulatory therapies for COVID-19.
Mathur, Poonam; Kottilil, Shyamasundaran.
  • Mathur P; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
  • Kottilil S; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Front Med (Lausanne) ; 9: 921452, 2022.
Article in English | MEDLINE | ID: covidwho-2089852
ABSTRACT

Purpose:

As COVID-19 disease progresses, the host inflammatory response contributes to hypoxemia and severe and critical illness. In these latter stages of disease, patients may benefit from immunomodulatory therapies to control the aberrant host inflammatory response. In this review, we provide an overview of these therapies and provide summaries of the studies that led to issuance of FDA Emergency Use Authorization or recommendation by the Infectious Diseases Society of America (IDSA). Materials and

methods:

We reviewed English-language studies, Emergency Use Authorizations (EUAs), and guidelines from March 2020 to present. Conclusion and relevance There are several therapies with proposed benefit in severe and critical COVID-19 disease. Few have been issued FDA EUA or recommendation by the Infectious Diseases Society of America (IDSA). Physicians should be familiar with the evidence supporting use of these therapies and the patient populations most likely to benefit from each.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Front Med (Lausanne) Year: 2022 Document Type: Article Affiliation country: Fmed.2022.921452

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Front Med (Lausanne) Year: 2022 Document Type: Article Affiliation country: Fmed.2022.921452